ASP 4396
Alternative Names: ASP-4396Latest Information Update: 19 Feb 2026
At a glance
- Originator Astellas Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein degraders
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 04 Feb 2026 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA to focus development on other candidates (IV) (Astellas Pharma pipeline, February 2026)
- 22 Oct 2025 Pharmacodynamics data from a preclinical study in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 (AACR-NCI-EORTC-2025)
- 16 Apr 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT06364696)